| scholarly article | Q13442814 |
| P356 | DOI | 10.3899/JRHEUM.090667 |
| P698 | PubMed publication ID | 19955053 |
| P50 | author | Irene van der Horst-Bruinsma | Q47264180 |
| Michael T Nurmohamed | Q90036771 | ||
| Yvo Smulders | Q98293916 | ||
| Erik H Serné | Q114430781 | ||
| Ben A C Dijkmans | Q114449351 | ||
| Izhar C van Eijk | Q114736010 | ||
| P2093 | author name string | Mike J L Peters | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atherosclerosis | Q12252367 |
| P304 | page(s) | 161-166 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | The Journal of Rheumatology | Q7743623 |
| P1476 | title | Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis | |
| P478 | volume | 37 |
| Q24603648 | 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis |
| Q90651753 | Assessing Endothelial Dysfunction in Patients with Ankylosing Spondylitis |
| Q88651282 | Assessment of aortic stiffness in patients with ankylosing spondylitis using cardiovascular magnetic resonance |
| Q45014971 | Atherosclerosis in male patients with ankylosing spondylitis: the relation with methylenetetrahydrofolate reductase (C677T) gene polymorphism and plasma homocysteine levels |
| Q38185646 | Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? |
| Q57673748 | Cardiomyopathy in ankylosing spondylitis |
| Q38124279 | Cardiovascular risk in the rheumatic disease patient undergoing orthopedic surgery |
| Q35496549 | Cardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation |
| Q64079453 | Carotid Intima-Media Thickness in Patients with Ankylosing Spondylitis: A Systematic Review and Updated Meta-Analysis |
| Q38936667 | Carotid intima media thickness as a marker of atherosclerosis in ankylosing spondylitis. |
| Q44925048 | Carotid intima-media thickness in spondyloarthritis patients |
| Q54246292 | Comorbidities in Spondyloarthritis. |
| Q57605596 | DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen |
| Q35884393 | Early cardiac valvular changes in ankylosing spondylitis: a transesophageal echocardiography study |
| Q44204800 | Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease |
| Q51329120 | Effect of tumor necrosis factor-α inhibitors on ambulatory 24-h blood pressure. |
| Q38177340 | Focus on the potential effects of treatments for spondylarthritides on cardiovascular risk |
| Q64111747 | Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis |
| Q34731291 | Increased risk of ischemic heart disease in young patients with newly diagnosed ankylosing spondylitis--a population-based longitudinal follow-up study. |
| Q35142805 | Increased risk of ischemic stroke in young patients with ankylosing spondylitis: a population-based longitudinal follow-up study. |
| Q87856583 | Ischemic heart disease and ankylosing spondylitis-assessing the role of inflammation |
| Q58765329 | Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment |
| Q36943007 | Predictors of Atherosclerosis in Ankylosing Spondylitis |
| Q40405924 | Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study |
| Q38911778 | Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis |
| Q54473799 | Subclinical atherosclerosis in ankylosing spondylitis: is there a role for inflammation? |
| Q38519523 | Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis. |
| Q53095551 | The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial. |
| Q59795584 | The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis |
| Q43665850 | The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome |
| Q46468090 | Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis |
| Q34164481 | Validated methods for assessment of subclinical atherosclerosis in rheumatology |
| Q85638822 | [ASAS/EULAR recommendations for the management of ankylosing spondylitis : evaluation of the 2010 update in the German-speaking area] |
| Q88462921 | [Becoming older with axial spondyloarthritis] |
| Q84514358 | [Development of morbidity and mortality in patients with spondyloarthritis] |
| Q95383352 | [Psoriatic arthritis : a permanent challenge for rheumatologists and patients--Part 1: epidemiology, pathogenesis and clinical course] |
Search more.